List of Velphoro drug patents
Velphoro is owned by Vifor Fresenius.
Velphoro contains Ferric Oxyhydroxide.
Velphoro has a total of 22 drug patents out of which 0 drug patents have expired.
Velphoro was authorised for market use on 27 November, 2013.
Velphoro is available in tablet, chewable;oral dosage forms.
Velphoro can be used as control of phosphorous levels in patients.
The generics of Velphoro are possible to be released after 26 May, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10933090 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US11013762 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US10925896 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US10682376 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US10925897 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US11013761 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
| US10695367 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(5 years from now) | |
|
US11013762
(Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(6 years from now) | |
|
US10925896
(Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(6 years from now) | |
|
US10925897
(Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(6 years from now) | |
|
US10933090
(Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(6 years from now) | |
|
US10682376
(Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(6 years from now) | |
|
US11013761
(Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(6 years from now) | |
|
US10695367
(Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(6 years from now) | |
| US9561251 | VIFOR FRESENIUS | Pharmaceutical compositions |
Jan, 2030
(6 years from now) | |
|
US9561251
(Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
Jul, 2030
(7 years from now) | |
| US11446252 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(11 years from now) | |
| US11234938 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(11 years from now) | |
| US10624855 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(11 years from now) | |
|
US10624855
(Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(12 years from now) | |
|
US11446252
(Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(12 years from now) | |
|
US11234938
(Pediatric) | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
May, 2035
(12 years from now) | |
Drugs and Companies using FERRIC OXYHYDROXIDE ingredient
Market Authorisation Date: 27 November, 2013
Treatment: Control of phosphorous levels in patients
Dosage: TABLET, CHEWABLE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic